Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression

PHASE2/PHASE3SuspendedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2019

Conditions
Depression
Interventions
DEVICE

PEER Interactive Report

A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.

Trial Locations (1)

27609

Carolina Partners, Raleigh

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Mount Sinai Hospital, New York

OTHER

lead

MYnd Analytics

INDUSTRY

NCT02988076 - Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression | Biotech Hunter | Biotech Hunter